Katie Coltart

Katie is a patent litigation specialist with a wealth of experience across the life sciences, telecoms and technology sectors. Katie is well-versed in dealing with major cross-border matters requiring significant coordination across multiple forums, and with a degree in chemistry and biology she is well-placed to advise on highly technical subject matters.

Katie has worked on the litigation of patents across a broad spectrum of technological subject matters, including those relating to antibody and other protein biologics, biosimilars, biological product development and screening platforms, medical devices, medical diagnostics and sequencing technologies, 2G, 3G, 4G and 5G telecommunications, connected cars, consumer products and FRAND/SEP licensing.

Work highlights

Katie’s experience includes :

• Advising Playtech Software in a patent dispute before the Unified Patent Court concerning an online gaming system
• Advising a major biosimilar manufacturer in preparation for the launch of one of its most important biosimilar products
• Advising a global pharmaceutical company on validity and enforcement issues in relation to a key RSV patent

• Acting for Pfizer in a patent dispute with Amgen concerning the development of bispecific antibodies for the treatment of multiple myeloma; a case that involved multiple other innovator claimants.
• Acting as UK and European coordinating counsel for Advanced Bionics (Sonova Group) against Med-El in a patent dispute concerning cochlear implant technology and spanning the UK, Germany, Netherlands, and the US.
• Acting as UK and cross-border coordinating counsel for Meril Life Sciences against Edwards Lifesciences in a long-running patent dispute concerning transcatheter heart valves and spanning numerous jurisdictions including the UK, Germany, France, Italy, Spain, Poland, Denmark, and the US.
• Acting as UK and global coordinating counsel for Regeneron against Kymab in a patent dispute that went all the way to the UK Supreme Court concerning antibody-producing transgenic mice and associated recombinant technologies; a case which required significant coordination with parallel proceedings on related patents in the US and across numerous patent offices
• Representing TCL in a FRAND/SEP case brought by Philips in the UK, including advising TCL on the novel approach of bringing counter-proceedings in France, resulting in the first case seeking a FRAND royalty determination in France.
• Coordinating a European defence strategy for a well-known biosimilars manufacturer in preparation for proceedings by the originator spanning Germany, France, Netherlands, Spain, Italy, Hungary, Sweden, Finland, Norway, Austria, Denmark and Ireland.
• Advising a global handset, computer and chipset manufacturer on worldwide SEP/FRAND policy matters. 

Katie is a member of the Law Society of England and Wales, the International Association for the Protection of Intellectual Property (AIPPI), and ChIPs Network (advancing women in tech, law and policy).

University of Oxford (Postgraduate Diploma in Intellectual Property Law and Practice, 2012); College of Law, London (Bachelor of Laws; Legal Practice Course, 2008); College of Law, London (Post-Graduate Diploma in Law, 2007); Durham University (B.Sc., Biology and Chemistry, 2006).